Navigation Links
Immtech Reports Fiscal Year End 2008 Results
Date:6/18/2008

NEW YORK, June 18 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced results for its fiscal year ended March 31, 2008.

For the fiscal year ended March 31, 2008, revenues increased to $9,717,000, as compared to $4,318,000 for the fiscal year ended March 31, 2007. The increase was primarily attributable to revenues from initial payments on license agreements recognized when the pafuramidine program was terminated. Loss from operations for the year ended March 31, 2008 was $10,952,000, as compared to a loss from operations of $11,662,000 for the year ended March 31, 2007. The loss was largely due to expenses related to the Phase III clinical trials during the year. Net loss attributable to common stockholders for the year ended March 31, 2008 was $11,042,000, or $0.71 per share, compared to a loss of $11,683,000, or $0.82 per share, in the previous year.

At March 31, 2008, unrestricted cash and cash equivalents were $5,996,000 as compared to $12,462,000 at March 31, 2007. For the same periods, restricted funds on deposit were $3,776,000 and $3,119,000, respectively.

The Company will hold a conference call on June 25th, 2008 at 2:00 P.M. (EDT) to present an update on Company progress and results for fiscal year end 2008. The User Access Code is # 52522128. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 220-6305 and callers outside the U.S. should call (706) 902-3163. Please call no later than 10 minutes prior to the scheduled start of the call to register. Information to access a recording of the conference call will be available starting on June 26th from the Immtech Pharmaceuticals web site (http://www.immtechpharma.com).

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug-resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the fiscal year ended March 31, 2008 being filed with the SEC on the date hereof, and in its other SEC filings and include, but are not limited to: (i) Immtech's ability to obtain additional funds; (ii) Immtech's ability to manage its remaining resources; (iii) Immtech's ability to continue as a going concern; (iv) Immtech's ability to retain key personnel; (v) the ability of Immtech's scientists and collaborators to discover new compounds; (vi) the availability of additional research grants; (vii) Immtech's ability to obtain regulatory approval of its drugs candidates; (viii) the success of Immtech's clinical trials; (ix) dependence upon and contractual relationship with partners; (x) Immtech's ability to protect its intellectual property; and (xi) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation, to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

3 Months

Ended Year Ended

March 31, March 31,

2008 2007 2008 2007

REVENUES $ 6,025 $ 1,339 $ 9,717 $ 4,318

OPERATING INCOME

(LOSS) $ 627 $ (3,216) $ (10,952) $ (11,662)

NET INCOME (LOSS)

TO COMMON

SHAREHOLDERS $ 560 $ (3,219) $ (11,042) $ (11,683)

NET LOSS PER

COMMON SHARE

BASIC AND DILUTED

Net Income $ 0.03 $ (0.22) $ (0.71) $ (0.82)

AVERAGE COMMON

SHARES OUTSTANDING

Basic and diluted 16,946,251 14,782,004 15,477,463 14,207,048


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Announces Results From Hepatitis C Discovery Program
2. Immtech Announces Update on Business Operations
3. Immtech Investor Conference Call Scheduled for February 22, 2008
4. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
5. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
6. Immtech Completes Malaria Prevention Trial
7. PreMD Reports Further Positive Meetings with the FDA
8. Herley Reports Third Quarter Results
9. Hawkins, Inc. Reports Fourth Quarter, Fiscal 2008 Results
10. China Medical Technologies Reports Fourth Quarter and Full Year Financial Results
11. Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Wont Cover It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow up is critical ... your dental team at presenting treatment, there will always be some patients who can’t ... and money on best practices when it comes to presenting treatment. After the ...
(Date:5/27/2017)... Santa Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... show cause for concern, but a new study from the Osteoarthritis Initiative ... vulnerable to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease Association’s ... eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be ... The American Parkinson Disease Association (APDA) is focused on advancing scientific research that ...
(Date:5/26/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) ... legislative activity and the latest regulatory concerns impacting RBMA members. The Legislative Education ... will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner in Mclean, ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... China and Canada joint tech company Laughing Face ... and detergent, and features a powerful disinfection process. The ... that washes and sanitizes women,s panties or babies, cloth diapers in ... ... require an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
Breaking Medicine Technology: